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ABSTRACT
Transfusion-related morbidity is an emerging challenge in chronically transfused patients with low-risk 
myelodysplastic syndromes (MDS). In these patients, transfusion-induced iron overload may represent a leading 
medical problem. However, although iron-chelating drugs are available, little is known about optimal diagnostic 
tools, predisposing factors, and the optimal management of these patients. In the current article, we provide 
recommendations for the diagnosis, prevention and treatment of iron overload in MDS and propose treatment 
response criteria. Consensus criteria and resulting recommendations were discussed and formulated by members 
of the MDS platform of the Austrian Society of Haematology and Oncology in a series of meetings and conferences 
in 2006 and 2007 . These recommendations should facilitate and assist in recognition of iron overload, selection 
of patients, timing of treatment, drug selection and the measurement of treatment responses.
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Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of 
myeloid neoplasms defined by abnormal differentiation and 
maturation of myeloid cells, bone marrow failure, and a genetic 
instability with an enhanced risk of transformation to secondary 
leukaemia [1–5]. Most patients with MDS present with 
transfusion-dependent anaemia with or without additional 
cytopenias [1–4]. MDS are classified according to their 
pathogenesis (de novo or secondary), cytological features, and 
specific karyotypes. A most useful classification system has been 
the proposal of the French-American-British (FAB) cooperative 
study group [6,7]. More recently, the World Health Organization 
(WHO) has worked out an updated classification [8] that 
represents an extension of the FAB proposal, with several 
modifications, that include the removal of the subvariant 
‘refractory anaemia with excess of blasts in transformation’ 
(RAEB-T; now in the group ‘acute myeloid leukaemia’, AML) 
and of chronic myelomonocytic leukaemia (CMML), recognition 
of the impact of multilineage dysplasia, and delineation of 
a cytogenetically defined variant, the 5q-syndrome [3,4,8]. 
However, in one particular WHO category, the prognosis and 
clinical picture may vary among patients depending on 
deregulated genes and the specific biological properties of the 
clone(s) [3–6]. Whereas some patients transform to leukaemia or 
die from complications of bone marrow failure within a short time, 
other patients survive for many years. The International Prognostic 
Scoring System (IPSS) and other scoring systems (like the 
Düsseldorf-score, Toyama-score, Mufti-score or Sanz-score) can 
assist in prognostication in MDS concerning survival and 
leukaemia-free survival [3–5,9]. All these score systems are 
based on multiple prognostic parameters.
In patients with low-risk MDS and transfusion-dependent 
anaemia, one important clinical feature is iron overload which 
develops in most cases [3,10,11]. Some of these patients develop 
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massive iron overload over time with consecutive organopathy 
(hepatopathy, cardiomyopathy and others) despite chelation 
therapy [10–12].
A number of different strategies aimed at counteracting iron 
overload in MDS have been proposed. A straightforward 
approach is to introduce iron-chelating agents such as 
desferoxamine, deferiprone (L1) or deferasirox (ICL670) [11,12]. 
Another approach is to prevent blood transfusions and thus 
iron overload by early therapeutic intervention with growth 
factors (erythropoietin with or without additional granulocyte 
colony-stimulating factor, G-CSF) or specific targeted drugs. In 
addition, current efforts are being made to define genetic factors 
that predispose to, and thus predict, rapid iron overload [13,14]. 
However, although several study groups have started to discuss 
criteria and recommendations [15–17], little is known about 
optimal diagnostic tools, predisposing factors and the optimal 
management of iron overload in these patients. In addition, 
most of these proposals lack suitable response criteria. During 
the past 12 months (October 2006–October 2007), an expert 
panel of the MDS platform of the Austrian Society for 
Haematology and Oncology has worked out definitions, 
criteria and recommendations for chronically transfused 
patients with MDS (based on literature data) in a series of 
panel-meetings. The respective outcome and consensus are 
reported herein.
Diagnosis, classification, and prognostication 
of MDS
When considering iron overload and the potential use of chelating 
agents, it is of importance to establish the diagnosis and variant 
of MDS, and to estimate survival and AML-free survival in these 
patients. Likewise, chelation therapy cannot be regarded as an 
important therapeutic manoeuvre in patients who are considered 
to transform to AML within a short time or are scheduled to receive 
chemotherapy.
Diagnostic criteria for MDS are available and should be applied 
in all patients [3,6–8]. For estimation of survival and AML-free 
survival, the IPSS is recommended as a gold standard of 
prognostication [9]. Other scoring systems and additional 
prognostic factors (not included in the IPSS such as LDH or age) 
may also be employed [18–23]. A clear advantage of the IPSS over 
other older scoring systems is that it also includes cytogenetic 
features, which appear to be of major prognostic significance 
[9]. With regard to iron overload, the recently proposed WPSS 
score may be of particular interest as this score includes the 
transfusion frequency (apart from cytogenetics and blast cells) as 
a prognostic variable and may also be used in the follow-up [23]. 
However, because of its general use and validation in numerous 
studies, the IPSS is still considered as gold standard in 
prognostication in MDS.
Definition of iron overload and recommended 
investigations
To determine and quantify iron overload, several different 
investigations have been proposed [24–30]. These investigations 
include serum ferritin levels, transferrin saturation, liver and 
cardiac imaging studies, and tissue histology (preferred: bone 
marrow, as this is often available; other principle options: liver or 
gastric mucosa) [24–30]. We recommend to assess the serum 
ferritin level and transferrin saturation together with liver 
enzymes and inflammation markers such as fibrinogen or 
C-reactive protein = CRP as a simple (and non-invasive) initial 
diagnostic step, in order to determine or exclude iron overload. 
A constant increase of ferritin exceeding 2000 ng mL
–1 should be 
considered as a relatively safe indication of iron overload provided 
that no severe coexisting active systemic inflammatory or active 
liver disease is present. Without effective therapy, ferritin levels 
and thus the iron load may further increase in chronically 
transfused MDS patients, and may cause severe clinical problems, 
and even organ failure of, for example, the heart and liver. 
As mentioned, an important limitation is that in the case of an 
ongoing inflammation, the ferritin level may also increase. In these 
patients, the test should be repeated in a symptom-free interval. 
If this is not possible because of constant chronic inflammation, a 
liver imaging test [recommended: Magnetic Resonance Imaging 
(MRI) or Superconducting QUantum Interference Device 
(SQUID)] should be considered [27–30]. In addition, it is  important  
to repeat ferritin levels in certain time intervals (every one to 
three months, depending on the severity of iron overload, 
dynamics in ferritin-increase, response to drugs and the overall 
situation of the patient)  in these patients to confirm or to exclude 
a further increase in the body iron burden. A liver biopsy is not 
recommended in these patients because of the risk of bleeding. 
However, it may be helpful to re-assess the bone marrow biopsy 
material, if available, and ask for signs of tissue iron overload. 
The value of gastric mucosa biopsies in the evaluation of iron 
overload in MDS has not been validated so far.
A number of different genetic polymorphisms and mutations 
are known to predispose to iron overload [31–34]. A good example  
is distinct HFE gene mutations, primarily C282Y and H63D. 
Homozygosity is often associated with frank haemochromatosis 
[31,32]. In contrast, the clinical significance of heterozygosity 
and of mutations (polymorphisms) in genes other than HFE 
are not well established. However, it is assumed that 
heterozygosity for HFE gene mutations, or other mutations, 
could predispose to iron overload, which can manifest when 
additional predisposing factors, such as chronic transfusions, 
are present [33,34]. Other gene products that have been 
implicated in the regulation of iron metabolism and storage 
are ferroportin 1 (FPN1), hemojuvelin (HFE2), and hepcidin 
(HAMP) [32].IRON OVERLOAD IN MDS
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More recently, it has been described that HFE gene 
polymorphisms (mutations) are frequently detected in patients 
with MDS [13,14]. Therefore, we recommend  establishing the HFE 
gene mutation status (and in the future probably also other 
iron-storage-related genes) in patients with MDS, at least when 
these patients present with signs of increased iron uptake before 
transfusion therapy (elevated serum ferritin, transferrin saturation 
> 70%), or have a case history of familial haemochromatosis, 
or have a rapid increase in serum ferritin levels after starting 
transfusion therapy.
Prevention of iron overload
A number of effective treatment options are available to treat 
anaemia and thus help to prevent iron overload and other 
transfusion-related side-effects in patients with MDS. A direct 
approach is to administer haematopoietic growth factors, i.e. 
erythropoietin with or without G-CSF [35–38]. Other drugs act as 
immunosuppressive agents (lenalidomide, cyclosporine-A, 
antithymocyte globulin, ATG) or stem cell-targeting therapy 
(chemotherapy, stem cell transplantation), and thereby may, 
indirectly, improve or even correct anaemia [3,39–41] (Table 1). 
An important aspect is that all these drugs act only in a subgroup 
of patients, which is in line with the notion that MDS represents 
an extremely heterogeneous group of stem cell neoplasms. 
Another interesting aspect is that the response to individual 
drugs can be predicted to a degree in these patients using 
established predictive parameters. Interestingly, in several 
instances (e.g. effects of erythropoietin), transfusion dependence 
itself has been recognized as an important predictive variable 
concerning the probability of a (erythroid) response [35–38].
Whatever treatment is considered, early intervention may be the 
optimal way to prevent iron overload. Erythropoietin (with or 
without G-CFS) is recommended for low risk MDS patients with 
transfusion-dependent anaemia in whom endogenous 
erythropoietin levels and the transfusion-frequency are low 
[35–38]. Thus, cytokine therapy is usually started in a relatively 
‘early’ phase of disease. However, a very early intervention, 
i.e. before transfusion therapy is initiated, may be questionable 
for several reasons. First, some of these patients may have a 
remarkably stable course and stable haemoglobin, at levels that do 
not require transfusions, and therefore would potentially be 
‘overtreated’ when starting too early with growth factors or other, 
maybe even mutagenic, drugs. Second, most drugs are only 
Table 1 Prevention and therapy of iron overload in MDS: proposed algorithm
Primary considerations: MDS subtype, IPSS, life expectancy, curative vs. palliative therapy plan, age, comorbidity, mental status
Laboratory investigations: Haematologic parameters and LDH, serum ferritin, transferrin-saturation, liver enzymes, inflammation 
parameters, (liver imaging studies, tissue biopsy, preferably bone marrow biopsy)
Prophylactic therapy: EPO ± G-CSF (Nordic score)
Lenalidomide (in 5q- syndrome patients)
ATG + CSA (hypoplastic MDS, HLADR15)
Demethylating agents (complex karyotype)
Chemotherapy ± SCT (AML-risk, donor, age)
Established iron overload: Consider therapy with chelating agents based on the following parameters:
Serum ferritin > 2000 ng mL
–1 (without signs of active inflammation or liver disease)
Transfusion dependent anaemia
Life expectancy of more than 2 years
Organopathy resulting from iron overload*
Planned chemotherapy or SCT†
Selection of chelating agents: 1. Desferoxamine (Desferal
®)‡
2. Deferasirox, ICL670 (Exjade
®)‡
3. Deferiprone, L1 (Ferriprox
®)‡
*In these cases, chelating agents should be considered even if the life expectancy is less than two years. †MDS patients with iron overload who undergo stem 
cell transplantation have a less favourable outcome (survival) compared to patients without iron overload. ‡If patients cannot tolerate, or do not respond to 
Desferal, Exjade should be applied unless kidney function is abnormal. If patients cannot tolerate Exjade, have significant side effects (kidney function) or 
have no response, Ferriprox or other experimental drugs should be considered (if possible in clinical trials). Abbreviations: MDS, myelodysplastic syndromes; 
IPSS, international prognostic scoring system; LDH, lactate dehydrogenase; EPO, erythropoietin; G-CSF , granulocyte-macrophage colony-stimulating factor;
 ATG, antithymocyte globulin; CSA, cyclosporine-A; SCT, stem cell transplantation; AML, acute myeloid leukaemia.www.ejci-online.com P.  VA L E N T  ET AL.
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approved for transfusion-dependent anaemia. Third, these drugs 
may also have side effects which should be taken into account 
in individual patients. Therefore, before starting therapy in 
non-transfused patients, it may be of great importance to estimate 
(i) the chance of a patient to develop transfusion-dependence in 
the near future, (ii) the chance of developing rapid iron-overload, 
and (iii) the probability of long term AML-free survival. In this 
regard, it may be of great importance to review the dynamics of 
anaemia in the past, to study all aspects of the disease including 
the IPSS, and to ask for signs of emerging iron overload or the 
genetic risk of developing iron overload.
Indication for chelation therapy and 
selection of patients
By consensus, the following groups of patients with MDS should 
be regarded as candidates for iron chelating therapy:
(i) Patients with frank iron overload (e.g. stable/increasing serum 
ferritin > 2000 ng mL
–1 without signs of active inflammation or 
liver disease) who are transfusion-dependent (at any frequency) 
and have a life expectancy of more than two years.
(ii) Patients who are transfusion-dependent, receive more than 
two red cell concentrates per month, at any ferritin level, and have 
a life expectancy of more than two years (exception: patients with 
frank iron deficiency, e.g. chronic gastrointestinal tract bleeding).
(iii) In select cases, iron chelating therapy can also be considered 
when life expectancy (estimate based on natural history of the 
disease) is less than two years. Examples are: planned curative 
therapy (stem cell transplantation), massive iron overload with 
consecutive organopathy considered to further reduce life 
expectancy, or massive iron overload that is judged to significantly 
reduce the quality of life (QOL).
Additional parameters that may influence the decision to treat 
with iron chelating agents in individual patients with MDS are age 
(geriatric aspects), social and mental features, comorbidity 
(organopathy) and the genetic status (HFE).
In patients with high ferritin levels (> 2000 ng mL
–1), iron 
chelating drugs can also be given, together with other specific 
drugs like cytokines (erythropoietin ± G-CSF), chemotherapy, 
or immunomodulating agents, with recognition of potentially 
harmful drug combination effects (e.g. effects of deferasirox and 
cyclosporine A, both of which may impair kidney function).
Selection of chelating agents
Several different iron chelating agents are available, including 
desferoxamine, deferiprone (L1), and deferasirox (ICL670). 
Whereas desferoxamine (Desferal
®) is usually applied 
subcutaneously, L1 = deferiprone (Ferriprox
®) and ICL670 
(Exjade
®) are administered orally [3,11]. The historical standard for 
iron chelation in MDS is desferoxamine [10–12]. However, more 
and more data suggest that ICL670, and probably L1, can be 
employed as effective alternative drugs, although it should be 
pointed out that most of this information stems from trials 
performed in non-MDS patients [42–46]. The major advantage of 
these drugs over desferoxamine is their oral use, as continuous 
subcutaneous infusions are inconvenient and may be associated 
with local side effects. On the other hand, both deferiprone and 
deferasirox can also produce relevant side effects. Notably, 
deferiprone has been described  as causing reversible neutropenia 
in about 5–10% of patients, as well as other side-effects, such as 
gastrointestinal symptoms, arthropathy, transient changes in liver 
enzymes and zinc deficiency, and therefore is not considered as 
an optimal alternative drug for MDS patients who may have 
pre-existing neutropenia and impaired neutrophil function. 
Deferasirox has been described as causing (in most cases reversible) 
impairment of renal function with elevation in serum creatinin 
levels, and in some cases even fatal irreversible renal failure, 
as well as other side-effects such as cytopenia, exanthema and 
an increase in liver enzymes. Therefore, both drugs must be 
administered with special caution and patients have to be 
monitored carefully. Likewise, in MDS patients treated with 
deferasirox, repeated examinations, starting with weekly tests, of 
the kidney function, including creatinine clearance measurements, 
should be performed. The various ‘pros’ and ‘cons’ for the use of 
the three chelators, in general and in MDS, have been discussed 
recently [47,48]. The major problem in MDS is that only a few 
studies and data are available for Exjade
® so far, and no data on 
L1/deferiprone are available. Nevertheless, deferasirox (Exjade
®) 
has recently been approved by the FDA and EMEA for the 
treatment of iron overloaded patients who cannot tolerate 
or do not respond adequately to desferoxamine.
The current recommendation for therapy of iron overload in 
MDS is to offer desferoxamine first and to examine the response 
to this drug. In patients who have no adequate response or are 
unable to tolerate the drug, we recommend the use of deferasirox 
(Exjade
®) (Table 1) provided that the kidney function (creatinine 
clearance) is normal, no renal disease is known, and the creatinine 
clearance remains stable during the first weeks of treatment. Mild 
changes in kidney function (slight increase in serum creatinine or 
slight decrease in creatinine clearance) may require dose 
adjustment (dose reduction), that usually does not lead to a 
complete loss of response to the drug. If dose reduction is not 
followed by a return of creatinine levels (creatinine clearance) to 
normal range, deferasirox should be stopped. In those patients 
who cannot tolerate or do not respond to Exjade
®, or have clear 
signs of impaired kidney function, Ferriprox
® or other 
experimental drugs (such as  triapine or immobilized 
desferrioxamine; or disease-targeting drugs for the prevention of 
iron overload) should be offered, if possible in clinical trials. In the 
case of Ferriprox
®, the potential for drug-induced neutropenia 
should be taken into account. In the case of severe neutropenia 
(agranulocytosis) or neutropenic infections following deferiprone IRON OVERLOAD IN MDS
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treatment, the drug should be stopped and G-CSF should be 
administered.
Monitoring of response and proposed 
response criteria
For monitoring iron overload and the response to therapy, 
we recommend performing serial measurements (every one to 
2 months) of serum ferritin levels together with liver enzymes 
and inflammation parameters. In fact, ferritin is a simple objective 
test and a relatively reliable and reproducible marker of iron 
overload unless the patient is suffering from an active hepatic 
disease or severe chronic inflammation. In such cases, serial 
imaging studies (MRI, SQUID) may be required. A rebiopsy (bone 
marrow) is usually not required. Depending on the drug applied, 
additional parameters need to be monitored, such as kidney 
function parameters or neutrophil counts.
Unfortunately, no generally accepted response criteria for iron 
depletion produced by chelating agents in MDS have been defined 
so far. We recommend the use of the following criteria and the 
resulting scoring system to measure responses to iron chelating 
agents in patients with MDS (Table 2).
A complete response (CR) is defined by a decrease in 
serum ferritin levels to < 2000 ng mL
–1 and a decrease by at least 
500 ng mL
–1. If the decrease is less than 500 ng mL
–1, a minor 
response (MiR) is reached. In other patients, a stable iron load 
(SIL) may be observed in the follow up. In these patients, 
serum ferritin levels are constantly elevated, but are less than 
4000 ng mL
–1. If ferritin levels further increase to > 4000 
(and by at least 500 ng mL
–1) the patient should be classified 
as a non-responder.
These criteria can be applied in patients receiving chelation 
therapy, but can also be applied in patients who have received 
drugs that can lead to transfusion-independence or at least to 
a decrease in transfusion frequency.
For how long should chelation be performed?
Currently available data suggest that transfusion-dependent and 
chelator-responding patients should be kept on iron chelating 
agents as long as a response can be documented, i.e. as long as no 
further marked (massive) increase in ferritin levels are seen 
(i.e. ferritin levels constantly < 4000 ng mL
–1).
In the case of very high serum ferritin levels or severe 
organopathy considered to result from iron overload, therapy 
can also be continued even when the patient is no longer 
transfusion-dependent (e.g. responds to lenalidomide). These 
patients should then be treated as long as they are classified 
as a responder, i.e. serum ferritin is < 4000 ng mL
–1, or decreases 
until ferritin has reached a level below 1000 ng mL
–1. 
Then, therapy with iron chelating agents should be stopped. 
If transfusion-dependence develops again in these patients, 
iron chelating therapy should be reintroduced. 
Concluding remarks and future perspectives
Transfusion-induced iron overload is an emerging clinical problem 
in patients with MDS. Whereas a subgroup of patients develop 
iron overload within a short time, others may not require chelation 
therapy over years despite repeated transfusions. So far, little is 
known about factors predisposing to iron overload in MDS, about 
the optimal management of these patients, and about the optimal 
treatment. The current article provides definitions for iron 
overload in MDS as well as recommendations for diagnostic 
investigations and the selection of patients for therapy. In addition, 
our article proposes therapeutic algorithms as well as response 
criteria. These recommendations and criteria should help in the 
management of patients with MDS in practice and in the conduct 
of clinical trials. In fact, since current recommendations and 
criteria, including that presented in this article, are mostly based 
on experience and data from non-MDS trials, prospective trials are 
warranted to establish the effect of chelation therapy on iron 
overload and survival in patients with MDS. Until the outcomes 
of such trials are reported, our proposal and similar recommendations 
may serve as a useful proposal for the treating physician.
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